Mark Lowdell
Founder at INMUNE BIO, INC.
Net worth: 18 M $ as of 2024-03-30
Profile
Mark Lowdell founded Achilles Therapeutics UK Ltd.
in 2016, Achilles Therapeutics Plc in 2020, INmune Bio, Inc. in 2015, where he is working as Chief Scientific & Manufacturing Officer from 2018, and Autolomous Ltd.
in 2019, where he is working as Director from 2021.
Dr. Lowdell also founded Kuur Therapeutics Ltd.
and Immune Ventures Ltd.
Dr. Lowdell also currently works at Royal Free London NHS Foundation Trust, as Director-Cellular Therapy from 2009, Royal Free Hospital Medical School, as Director-Centre for Cell, Gene & Tissue, University College London, as Professor from 1994, and International Society For Cell & Gene Therapy, as Vice President.
Dr. Lowdell received his doctorate degree in 1992 from St Bartholomew's Hospital Medical College and doctorate degree in 1992 from Blizard Institute.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
INMUNE BIO, INC.
8.38% | 2024-04-18 | 1,510,806 ( 8.38% ) | 18 M $ | 2024-03-30 |
Mark Lowdell active positions
| Companies | Position | Start |
|---|---|---|
| INMUNE BIO, INC. | Founder | 2015-08-31 |
| University College London | Corporate Officer/Principal | 1993-12-31 |
Royal Free London NHS Foundation Trust
 Royal Free London NHS Foundation Trust Hospital/Nursing ManagementHealth Services Royal Free London NHS Foundation Trust operates hospitals and clinics. The company was founded on July 1, 2014 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 2009-01-31 |
| Royal Free Hospital Medical School | Corporate Officer/Principal | - |
| International Society For Cell & Gene Therapy | Corporate Officer/Principal | - |
| Autolomous Ltd. | Founder | 2019-01-31 |
Former positions of Mark Lowdell
| Companies | Position | End |
|---|---|---|
| Immune Ventures Ltd. | Founder | - |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Founder | - |
| ACHILLES THERAPEUTICS PLC | Founder | - |
| ░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | - |
Training of Mark Lowdell
| St Bartholomew's Hospital Medical College | Doctorate Degree |
| Blizard Institute | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ACHILLES THERAPEUTICS PLC | Health Technology |
| Private companies | 7 |
|---|---|
Kuur Therapeutics Ltd.
 Kuur Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom. | Health Technology |
Royal Free London NHS Foundation Trust
Royal Free London NHS Foundation Trust Hospital/Nursing ManagementHealth Services Royal Free London NHS Foundation Trust operates hospitals and clinics. The company was founded on July 1, 2014 and is headquartered in London, the United Kingdom. | Health Services |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Health Technology |
| INmune Bio, Inc. | |
| Immune Ventures Ltd. | |
| International Society For Cell & Gene Therapy | |
| Autolomous Ltd. |
- Stock Market
- Insiders
- Mark Lowdell
